Neural Regeneration Research ›› 2013, Vol. 8 ›› Issue (10): 938-947.doi: 10.3969/j.issn.1673-5374.2013.10.009

Previous Articles     Next Articles

Therapeutic effects and safety of olcegepant and telcagepant for migraine A meta-analysis

Gang Yao1, 2, Tingmin Yu1, Ximei Han1, 3, Xijing Mao1, Bo Li4   

  1. 1 Department of Neurology, Second Hospital, Jilin University, Changchun 130041, Jilin Province, China
    2 Department of Neurology, First Hospital, Jilin University, Changchun 130021, Jilin Province, China
    3 Department of Neurology, Chifeng Municipal Hospital, Chifeng 024000, Inner Mongolia Autonomous Region, China
    4 Research Room of Epidemiology and Health Statistics, School of Public Health, Jilin University, Changchun 130021, Jilin Province, China
  • Received:2012-10-24 Revised:2013-01-27 Online:2013-04-05 Published:2013-04-05
  • Contact: Tingmin Yu, M.D., Professor, Master’s supervisor, Department of Neurology, Second Hospital, Jilin University, Changchun 130041, Jilin Province, China, ytm_396@163.com.
  • About author:Gang Yao☆, Studying for doctorate.

PDF

1580

Abstract:

OBJECTIVE: To evaluate the therapeutic effects and adverse reactions of olcegepant and telcagepant for the treatment of migraine.
DATA RETRIEVAL: We identified studies using Medline (1966-01/2012-06), PubMed (1966-01/2012-06), Scopus (1980-01/2012-06), Cochrane Central Register of Controlled Trials (1980-01/2012-06) and China National Knowledge Infrastructure (1980-01/2012-06).
SELECTION CRITERIA: The included studies were double-blind, randomized and placebo-controlled trials of olcegepant or telcagepant for the treatment of single acute migraine in patients with or without aura. Adverse reaction data were also included. Two independent investigators performed quality evaluation and data extraction using Jadad scoring. Meta-analyses were undertaken using RevMan 5.0.25 software.
MAIN OUTCOME MEASURES: Pain relief rate, pain-free rate, and incidence of adverse reactions were measured in patients 2 and 24 hours after injection of olcegepant and oral telcagepant.
RESULTS: Six randomized, controlled trials were included. Meta-analysis demonstrated that compared with placebo, the pain relief rate (odds ratio, OR = 5.21, 95% confidence interval, CI: 1.91–14.2, P < 0.01) and pain-free rate (OR = 31.11, 95% CI: 3.80–254.98, P < 0.01) significantly increased 2 hours after 2.5 mg/d olcegepant treatment. Pain relief rate and pain-free rate 2 and 24 hours after treatment with telcagepant 150 mg/d and 300 mg/d were superior to placebo (P < 0.01). Moreover, the remission rate of unrelenting headache was higher after 24 hours of 300 mg/d telcagepant treatment compared with 150 mg/d (OR = 0.78, 95% CI: 0.62–0.97, P < 0.05). The incidence of adverse reactions with olcegepant was not significantly greater than placebo (P = 0.28), but within 48 hours of administration of telcagepant 300 mg/d, the incidence of adverse reactions was higher than placebo (OR = 1.21, 95% CI: 1.04–1.42, P < 0.01). Few studies have compared the therapeutic effects of olcegepant and telcagepant.
CONCLUSION: The calcitonin-gene-related peptide receptor antagonists olcegepant and telcagepant have shown good therapeutic effects in the treatment of migraine. Moreover, the incidence of adverse reactions compares favorably with placebo, although liver transaminases may become elevated after long-term use.

Key words: neural regeneration, evidence-based medicine, migraine, telcagepant, MK-0974, olcegepant, BIBN4096, treatment, meta-analysis, neuroregeneration